1.70
-0.10 (-5.31%)
| Previous Close | 1.79 |
| Open | 1.74 |
| Volume | 995,178 |
| Avg. Volume (3M) | 2,655,318 |
| Market Cap | 575,738,944 |
| Price / Sales | 83.98 |
| Price / Book | 1.80 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 16 May 2025 |
| Operating Margin (TTM) | -944.53% |
| Diluted EPS (TTM) | -2.11 |
| Total Debt/Equity (MRQ) | 1.92% |
| Current Ratio (MRQ) | 9.03 |
| Operating Cash Flow (TTM) | -130.41 M |
| Levered Free Cash Flow (TTM) | -52.19 M |
| Return on Assets (TTM) | -18.02% |
| Return on Equity (TTM) | -106.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Nuvation Bio Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 1.63 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 19.21% |
| % Held by Institutions | 58.67% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Decheng Capital Llc | 31 Dec 2024 | 25,954,439 |
| Omega Fund Management, Llc | 31 Dec 2024 | 13,072,340 |
| Octagon Capital Advisors Lp | 31 Dec 2024 | 9,202,907 |
| Mpm Bioimpact Llc | 31 Dec 2024 | 4,164,178 |
| Tang Capital Management Llc | 31 Dec 2024 | 3,900,000 |
| Aisling Capital Management Lp | 31 Dec 2024 | 2,541,009 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (HC Wainwright & Co., 489.97%) | Buy |
| 10.00 (Jones Trading, 489.97%) | Buy | |
| Median | 10.00 (489.97%) | |
| Low | 6.00 (JMP Securities, 253.98%) | Buy |
| Average | 8.67 (411.50%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 2.07 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 23 Apr 2025 | 6.00 (253.98%) | Buy | 2.08 |
| Jones Trading | 12 Mar 2025 | 10.00 (489.97%) | Buy | 2.24 |
| HC Wainwright & Co. | 10 Mar 2025 | 10.00 (489.97%) | Buy | 1.88 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |